<DOC>
	<DOCNO>NCT01457118</DOCNO>
	<brief_summary>The study objective open label , multicenter study provide access NKTR-102 treatment subject previously enrol NKTR-102 study without sign disease progression since receive NKTR-102 . In addition study evaluate safety continue exposure NKTR-102 , observe disease status survival status subject receive NKTR-102 , evaluate efficacy NKTR-102 subject advance metastatic solid tumor .</brief_summary>
	<brief_title>An Extension Study NKTR-102 Cancer Patients Previously Enrolled NKTR-102 Studies</brief_title>
	<detailed_description />
	<criteria>Inclusion : 1 . Received prior treatment NKTR102 2 . Free disease progression since receive NKTR102 3 . Adequate bone marrow organ function 4 . Treatment NKTR102 extension study begin within 8 week receipt last dose NKTR102 5 . Agree use adequate contraception Exclusion : 1 . Treatment anticancer therapy last dose NKTR102 prior study first dose NKTR102 extension study 2 . A toxicity require 3rd dose reduction take NKTR102 schedule receive dose &lt; 70 mg/m2 upon entry study 3 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Open Label multicenter extension study advance solid tumor</keyword>
</DOC>